Saint Luke's Cancer Institute provides early detection, expert diagnosis, personalized treatment options, and survivorship support to every patient.
Kansas City, MO
Joined January 2023
- Tweets36
- Following52
- Followers30
- Likes27
Congratulations to Rich Liekweg, BJC Health System CEO, who announced his plans to retire on October 1, 2025.
BJC is pleased to announce that Nick Barto, current BJC Health System President, will succeed Rich as President and CEO of BJC Health System: heyor.ca/j1yUMR
Saint Luke’s Cancer Institute is featured in ACCC’s new video series on using genomics to expand access to clinical trials.
Watch the series from ACCC for more on how our team is advancing the future of cancer care: heyor.ca/GT83ms
Saint Luke's Cancer Institute's new Comprehensive Cancer Program is now open on the campus of Saint Luke's North Hospital-Barry Road! 🎉
Take an inside look with Dan and Dr. Zach Nicholas, Director of Radiation Oncology, to see all this expanded space has to offer.
Saint Luke's Cancer Institute retweeted
#ASCO25 Day 1: it was great getting the @SLCI_KC crew together outside of the office to catch up! @saintlukeskc
Saint Luke's Cancer Institute retweeted
Happy to work in a practice with great people that enjoy blowing off some steam at the end of the week. Cheers to many more happy hours! @saintlukeskc @SLCI_KC
Saint Luke's Cancer Institute retweeted
Calling all thoracic oncologists - Saint Luke’s in Kansas City is hiring! We have robust precision and research programs. DM me to get more information on how to join the wonderful folks in our practice! saintlukes.wd1.myworkdayjobs… @saintlukeskc
Saint Luke's Cancer Institute retweeted
Join us alongside gastrointestinal medical oncologist @MarcRothMD of @StLukesSTL April 25 at 1pm EST for a deep dive into biomarker testing and how it fits into your care plan!
Register today!
fightcrc.zoom.us/webinar/reg…
We’re excited to announce the recent opening of PRISM-1 via @arcusbio, a P3 trial for pts with met pancreatic cancer! Trial is exploring gem/abraxane +/- quemliclustat. Oncology needs panc trials! 👏 👏👏@saintlukeskc
trials.arcusbio.com/study/pr…
Saint Luke's Cancer Institute retweeted
Thrilled to present our research at @ASCO #GI25 highlighting the efficacy of HER-2 targeted therapies in #biliarytractcancers!!!
Grateful to my mentor @MarcRothMD for his guidance and all the co-authors for their support.
@KrityaMangesh
@umkcIM @SLCI_KC
#MedTwitter
Saint Luke's Cancer Institute retweeted
Thrilled to share that our research project has been accepted for poster presentation at #ASCOGI25!!!
Grateful to my mentor @MarcRothMD for his support and guidance.
@ASCO @umkcIM @SLCI_KC
#hemoncaspirant
#CancerResearch
Saint Luke's Cancer Institute retweeted
Our correspondence is now available on @TheLancet!
Differences in HCC etiology may contribute to the positive result of camrelizumab plus rivoceranib in CARES-310 trial, in contrast to other IO+TKI trials. Thank you @MarcRothMD @SLCI_KC for the support.
thelancet.com/journals/lance…
Saint Luke's Cancer Institute retweeted
More than happy to have a review on predictive biomarkers for irAE.
Prospective studies that capture irAE proactively better and incorporating scoring system to predict irAE are the future directions.@dhruvsxu @RamSubraMD @Khan7013 @SLCI_KC @Cancers_MDPI
mdpi.com/2072-6694/16/6/1225
Saint Luke's Cancer Institute retweeted
As #PancreaticCancerAwarenessMonth comes to a close, I wanted to highlight some of our amazing @SLCI_KC #GI #Cancer team members who rose money for the @NatPancFdn Pancreas Bowl! We had a blast raising money for a good cause @saintlukeskc #teamsaintlukes – at Overland Park, KS
Saint Luke's Cancer Institute retweeted
The day we’ve been waiting for! @US_FDA approves fruquitinib for refractory met #colorectal #cancer providing another option for our patients! Thank you to mentor @CathyEngMD and others on this tremendous effort! @SLCI_KC @saintlukeskc
onclive.com/view/fda-approve…
Saint Luke's Cancer Institute retweeted
Check out our new case report on a patient w #colorectal #cancer and a T790M mutation who responded to targeted therapy w osimertinib. Collab between @SLCI_KC Center for Precision Oncology and @UMKC. wjgnet.com/1948-5204/full/v1… @dhruvsxu @JBuckleyMD @saintlukeskc #teamsaintlukes
📢 New provider spotlight: We're excited to welcome Norin Ansari MD MPH to Saint Luke's Cancer Institute! She comes from @YaleCancer @YaleHemOnc fellowship and is happy to back home in the Midwest. Dr. Ansari is seeing new patients at @SLCI_KC East in Lee's Summit, MO. Welcome!🤗
St Luke's precision oncology program reports improved outcomes for patients with @saintlukeskc molecular tumor board-directed therapy at the ESMO conference in Madrid
Dr. Bansal keeps his ongoing research into patient subgroups that benefit from immunotherapy. Being presented at @sitcancer 2023 annual conference.
